Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Govitecan vs TPC in HR+/HER2- Metastatic Breast Cancer
NCT03901339Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- May 2019
- Primary completion
- Oct 2023
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 9
01
Overview
A Phase 3 trial of sacituzumab govitecan in breast cancer, sponsored by Gilead Sciences. Started May 2019; status: completed.
02
Drugs
sacituzumab govitecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03901339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03901339.